Pembrolizumab,Lenvatinib,Sunitinib
Merck,Pfizer,eisai
['clear study', 'gu ', 'prostate', 'pembro']
happening now: gu non prostate mini orals shows update of clear study, median f/u 33 months:
- pfs maintained across risk groups
- orr 17%, primary pd 5%
- longer f/u needed for good risk
- reading out for pts post 2 years pembro, encouraging #esmo22 
Medical Oncologist, @HamHealthSci | Assistant Professor, @McMasterU | Former Fellow, @DanaFarber | Academic focus: genitourinary & rare cancers | Views my own.